Subtype-directed breast cancer treatment comprises endocrine therapy for all HR+ tumors, HER2-targeted therapy plus chemotherapy for all HER2+ tumors, and chemotherapy for TNBC (Figure 1) [12]. This evidence concerns the gene ERBB2 and breast carcinoma.